iScience (Apr 2021)

The sphingosine kinase 1 activator, K6PC-5, attenuates Ebola virus infection

  • Gergely Imre,
  • Verena Krähling,
  • Madeleine Eichler,
  • Sandra Trautmann,
  • Nerea Ferreirós,
  • M. Javad Aman,
  • Fatah Kashanchi,
  • Krishnaraj Rajalingam,
  • Stefan Pöhlmann,
  • Stephan Becker,
  • Dagmar Meyer zu Heringdorf,
  • Josef Pfeilschifter

Journal volume & issue
Vol. 24, no. 4
p. 102266

Abstract

Read online

Summary: Ebola virus (EBOV) is responsible for outbreaks with case fatality rates of up to 90% and for an epidemic in West Africa with more than ten thousand deaths. EBOV glycoprotein (EBOV-GP) is the only viral surface protein and is responsible for viral entry into cells. Here, by employing pseudotyped EBOV-GP viral particles, we uncover a critical role for sphingolipids in inhibiting viral entry. Sphingosine kinase 1 (SphK1) catalyzes the phosphorylation of sphingosine to sphingosine 1-phosphate (S1P). The administration of the SphK1 activator, K6PC-5, or S1P, or the overexpression of SphK1 consistently exhibited striking inhibitory effects in EBOV-GP-driven entry in diverse cell lines. Finally, K6PC-5 markedly reduced the EBOV titer in infected cells and the de novo production of viral proteins. These data present K6PC-5 as an efficient tool to inhibit EBOV infection in endothelial cells and suggest further studies to evaluate its systemic effects.

Keywords